On August 5, a delegation led by Xavier Michon Lehnebach, Chairman of the Supervisory Board of the Global Alliance of SMEs (GASME), visited UnicornShell's Beijing business center and North China production demonstration base. The visit focused on the company's technological achievements and industrial layout in plant-based pharmaceutical excipients, with in-depth discussions on international cooperation in plant-based capsules and cross-border resource integration for SMEs.

01

Site visit to North China demonstration base, focusing on plant capsule industrialization

The delegation toured the production workshops and quality control center of the North China production demonstration base, reviewing the full process of plant-based empty capsules from raw material screening and manufacturing to finished-product inspection. Accompanied by UnicornShell executives, the guests examined the company's self-developed fully servo-driven intelligent production lines and asked detailed questions about plant capsule production capacity, equipment adaptability, and international certification systems.

The North China demonstration base is UnicornShell's first established large-scale production cluster, with all products exported to overseas markets. Built in full compliance with pharmaceutical GMP standards, the base achieves a 99.99% machine-feeding qualification rate.

02

Beijing business center discussions on global supply chain cooperation

At the Beijing business center, both sides held talks on the global supply landscape and cooperation models for plant-based capsules. Mr. Lehnebach introduced GASME's platform resources and priorities in promoting cross-border cooperation among SMEs worldwide, and expressed strong interest in UnicornShell's 27-year technical accumulation in plant-based pharmaceutical excipients.

UnicornShell executives presented the company's core technology strengths and global capacity strategy. The company currently holds an IP portfolio of more than 30 assets, including national invention patents, international invention patents, utility model patents, and software copyrights. Its core products have obtained U.S. FDA certification, Halal certification, and European BRC certification, giving it market-access qualifications for major global markets. In May 2026, UnicornShell extended the shelf life of its plant-based empty capsules from 48 to 60 months, and the relevant change filing was completed with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).

Mr. Lehnebach noted that GASME is committed to building international cooperation platforms for SMEs and facilitating pragmatic links in technology, markets, and resources. He said UnicornShell's technical capability and industrialization experience in plant-based capsules align closely with the alliance's goal of advancing green pharmaceutical industry upgrading, and expressed hope for further follow-up cooperation.

03

27 years in plant capsules, entering the global first tier

Since launching plant capsule R&D in 1999, UnicornShell has spent 27 years building a complete technology chain from laboratory to industrialization. The company operates a Shanghai R&D and operations headquarters along with multiple production demonstration bases, and plans to establish nationwide annual plant capsule capacity at the "hundred-billion-level" scale by 2028, with products sold to markets across multiple countries and regions.

The visit provides a new opportunity for UnicornShell to deepen international exchange and expand its global cooperation network. Moving forward, the company will uphold its mission of "promoting medication safety and protecting human health," leverage its global capacity layout and technology innovation strengths, and work with international partners to advance the high-quality development of the plant-based pharmaceutical excipient industry.